GeneDx

50 articles about GeneDx

• GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  9/22/2023

  GeneDx announced that, effective as of October 1, the compensation committee of GeneDx’s board of directors granted newly-hired employees 133,998 restricted stock units as inducements material to each employee entering into employment with GeneDx.

• GeneDx Announces Evolution of Executive Leadership Team

  9/11/2023

  GeneDx a leader in delivering improved health outcomes through genomic and clinical insights, announced the expansion and evolution of its executive leadership team with the appointment of Melanie Duquette as Chief Growth Officer and Jennifer Brendel as Chief of Corporate Affairs.

• GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced

  9/6/2023

  GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced a monumental accomplishment in its ongoing commitment to deliver personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery.

• GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine

  8/21/2023

  GeneDx today announced that Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG) has published a peer-reviewed research analysis resulting from a multi-lab collaboration involving GeneDx.

• GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 09, 2023

  8/9/2023

  GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, announced that, effective as of August 8, 2023, the compensation committee of GeneDx’s board of directors granted newly-hired employees 23,769 restricted stock units as inducements material to each employee entering into employment with GeneDx.

• PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

  8/7/2023

  PacBio and GeneDx today announced a research collaboration with the University of Washington to study the capabilities of HiFi long-read whole genome sequencing (WGS) to increase diagnostic rates in pediatric patients with genetic conditions.

• GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options

  7/19/2023

  GeneDx and Prognos Health, the largest real-world integrated data marketplace, today announced a strategic partnership to shorten the treatment odyssey for rare disease patients via real world data.

• GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

  7/18/2023

  GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the second quarter of 2023 after the market closes on Tuesday, August 8, 2023.

• GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium

  6/28/2023

  GeneDx today announced it will present new data on urine mitochondrial DNA testing at the 2023 United Mitochondrial Disease Foundation’s (UMDF) Mitochondrial Medicine Symposium in Charlotte, North Carolina, June 28 - July 1, 2023.

• GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants

  6/26/2023

  GeneDx (Nasdaq: WGS) today published a paper in Nature Methods, titled “Multiscale analysis of pangenomes enables improved representation of genomic diversity for repetitive and clinically relevant genes,” in which researchers developed a new computational tool, the PanGenome Research-Tool Kit (PGR-TK), for scalable analysis of clinically relevant genes that were previously too complex to analyze.

• GeneDx to Participate in Upcoming Investor Conferences in June 2023

  5/24/2023

  GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, announced that management will participate at the following investor conferences in June.

• GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations

  5/23/2023

  GeneDx today announced that it will participate in multiple presentations at the World Orphan Drug Congress in Washington, D.C., May 23-25, 2023.

• GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement

  5/22/2023

  GeneDx announced that it had received a letter from The Nasdaq Stock Market LLC stating that, because the Company’s Class A common stock had a closing bid price at or above $1.00 per share for a minimum of ten consecutive business days, the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450, and that the matter is now closed.

• GeneDx Reports First Quarter 2023 Financial Results and Business Highlights

  5/9/2023

  GeneDx Holdings Corp., a leader in delivering improved health outcomes through genomic and clinical insights, reported its financial results for the first quarter of 2023.

• GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option

  5/4/2023

  GeneDx announced the availability of its GenomeXpress® and GenomeSeqDx® whole genome sequencing tests with buccal swabs as an alternative sample collection option for biological parents or other immediate family members.

• GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders

  5/3/2023

  GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, announced a clarification regarding the CUSIP number for the Company’s public warrants.

• GeneDx Announces Reverse Stock Split

  4/28/2023

  GeneDx today announced that its board of directors has approved a 1-for-33 reverse stock split of the Company’s Class A common stock.

• GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023

  4/18/2023

  GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, announced it will release financial results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023.

• GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel

  4/3/2023

  GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Devin K. Schaffer has been appointed General Counsel, effective April 24, 2023.

• GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”

  3/20/2023

  GeneDx Holdings Corp today announced it is continuing to support whole genome sequencing (WGS) and interpretation services for the GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study.